moomoo ID:0
Log Out
  • 中文繁体
  • 中文简体

Download App

Log in to access Online Inquiry
wrote a post12/27/2021 17:57

The Week Ahead In Biotech (Dec.26-Jan. 1): Xeris FDA Decision, Pending Clinical Readouts In Focus In Final Week Of Year

The week's news was headlined by the Food and Drug Administration issuing emergency use authorizations for two oral COVID-19 antiviral pills. $Pfizer(PFE.US)$ received authorization for its oral drug Paxlovid on Wednesday, followed by $Merck & Co(MRK.US)$ molnupiravir.

$BiondVax制药(BVXV.US)$ rallied strongly after it announced in-licensing of nano-sized COVID-19 antibody.

$Allakos(ALLK.US)$ was among the worst performers of the week after the company's investigational compound flunked late-stage studies in inflammation of the digestive tract.

Here are the key biopharma catalysts for the unfolding week:

The FDA is scheduled to announce its verdict on $Xeris Pharmaceuticals(XERS.US)$ new drug application for Recorlev (levoketoconazole), an investigational adrenal steroidogenesis inhibitor in development for the treatment of patients with endogenous Cushing's syndrome.

Clinical Readouts/Presentations
Year-end Releases

$Anavex Life Sciences(AVXL.US)$: Top-line results from the second placebo-controlled AVATAR Phase 2/3 study of Anavex2-73 for the treatment of adult patients with Rett syndrome and top-line results from the placebo-controlled Phase 1 ANAVEX 3-71-001 study evaluating ANAVEX3-71 in humans

$Vanda Pharmaceuticals(VNDA.US)$: results of Phase 3 study off tradipitant in gastroparesis

Moomoo is an app offered by Moomoo Techonologies Inc. that provides information about investments. Moomoo Technologies is not an investment adviser or a broker-dealer and it provides neither investment or financial advice nor securities trading services. All contents such as comments and links posted or shared by users of the community are opinions of the respective authors only and do not reflect the opinions, views, or positions of Moomoo Technologies, its affiliates, or any employees of Moomoo Technologies or its affiliates. You are advised to consult a qualified financial or tax advisor for your personal financial planning and tax situations.
Sign in to post a comment